Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
Status:
Completed
Trial end date:
2017-08-30
Target enrollment:
Participant gender:
Summary
Investigators aim to determine Epidiolex's promise as a pharmacotherapy for cannabis use
disorder. Investigators hypothesize that Epidiolex, when added to medical management, will
result in greater reductions in marijuana use compared to placebo as measured by the 2
primary outcome measures: 1) quantitative THC levels and 2) self-report by Timeline Follow
Back. Secondary outcome measures will include treatment retention, patient satisfaction,
cannabis withdrawal, cannabis craving, depressive symptoms, anxiety symptoms, , compliance,
and cigarette use.